India’s Stance on the WHO Pandemic Treaty Highlights Global Vaccine Inequities and Administrative Lapses

India, representing a substantial segment of the Global South, has formally signaled its disquiet over the protracted gestation of the World Health Organization's pandemic preparedness treaty, a disquiet rooted in the grievous experience of delayed and costly vaccine acquisition during the Covid‑19 emergency.

The underlying grievance, articulated by ministers of health and senior bureaucrats alike, contends that the existing international order, dominated by affluent Western nations, furnished its own populations with ample immunological resources whilst consigning Indian citizens and their counterparts in similarly positioned economies to an avoidable mortality burden heightened by inflated procurement charges.

In response, the Indian government has placed the forthcoming treaty negotiations under a rigorous litmus test, demanding that any final instrument incorporate legally binding obligations for equitable vaccine distribution, transparent pricing mechanisms, and enforceable accountability structures capable of compelling high‑income states to honour their pledges without recourse to diplomatic evasion.

Western delegates, particularly those hailing from European capitals, have repeatedly portrayed the treaty as an inevitable culmination of multilateral goodwill, yet have conspicuously sidestepped the most palpable impasse by offering vague assurances whilst eschewing any concession that would diminish the privileged access to intellectual property and surplus stockpiles presently enjoyed by their constituencies.

Observers within Indian civil society have warned that the perpetuation of such asymmetries may engender a renewed cycle of public health neglect, whereby future pandemics could exploit the same structural lacunae that allowed SARS‑CoV‑2 to ravage communities already burdened by inadequate healthcare infrastructure and chronic socioeconomic disparity.

In the administrative domain, the Ministry of Health and Family Welfare has issued a communique asserting that it remains committed to collaborative engagement, yet the language of the statement betrays a measured reluctance to concede substantive policy shifts that might curtail domestically preferred procurement strategies reliant upon private‑sector partnerships and indigenous vaccine development programmes.

Should the Indian Constitution’s guarantee of the right to health be interpreted to obligate the central government to secure legally enforceable clauses within any forthcoming WHO pandemic treaty that compel equitable vaccine allocation, price transparency, and compulsory licensing, thereby rendering the state accountable before the judiciary for any failure to protect its most vulnerable citizens from preventable disease?

Might the existing framework of the International Health Regulations be insufficient to address the systemic disparity revealed by the Covid‑19 experience, thereby necessitating a legislative amendment that explicitly sanctions sanctions against nations that persist in hoarding medical countermeasures, and if so, what constitutional or parliamentary mechanisms would empower Indian legislators to enact such punitive provisions without infringing upon sovereign diplomatic prerogatives?

Could the reliance on public‑private partnership models for pandemic preparedness be deemed a dereliction of the state’s duty to provide universal health services, and would a judicial review of such arrangements reveal violations of the constitutional directive principles of state policy that prescribe the equitable distribution of essential medicines and the prevention of exploitation by profit‑driven entities?

Is it within the competence of the Union Ministry of Health, in conjunction with the Ministry of Law and Justice, to draft a domestic statutory instrument that transposes the obligations of any WHO pandemic treaty into binding Indian law, thereby furnishing citizens with a judicially enforceable remedy should the government neglect its treaty‑derived responsibilities?

Might the Supreme Court’s jurisdiction under Article 32, traditionally invoked to enforce fundamental rights, be expansively interpreted to compel the executive branch to disclose a fully itemised and publicly accessible ledger of all vaccine procurement agreements, thereby illuminating any procedural improprieties, preferential allocations, or profiteering schemes that would contravene constitutional guarantees of equality before the law, non‑discrimination, and the overarching public interest?

Will the eventual adoption of a WHO pandemic treaty, should it incorporate robust dispute‑resolution mechanisms and enforceable penalties, furnish a viable platform for India to challenge expatriate pharmaceutical monopolies, thereby rectifying the historic inequities that have rendered its population vulnerable to preventable morbidity and mortality in successive health crises?

Published: May 10, 2026